timeline

three decades of Kode Technology

From blood-group glycolipids to synthetic Function-Spacer-Lipid constructs, kodecyte products and Kode Immunoeducers for cancer.

Kode Technology timeline: from R&D tools to immunoeducers

  • Kode Biotech — the platform
  • Kode Agalimmune — AGI-134
  • KodeRx — K5K
  • Kode Veterinary Sciences — Kv9

Natural glycolipids · 1988–2002

  1. 1988

    Stephen Henry publishes his first research on blood-group glycolipids: the science that Kode Technology evolved from.

  2. 1996

    Stephen Henry begins using purified natural glycolipids to modify red cells, and makes a prototype quality-control system for blood banks.

  3. 1999

    The technology is named KODE.

Synthetic FSL constructs · 2003–today

  1. 2003

    The first working synthetic Function-Spacer-Lipid (FSL) construct, on 26 August: the birth of Kode Technology.

  2. 2004

    First patent filed, for synthetic membrane anchors.

  3. 2005

    The first kodecyte product, CSL Biosciences' Securacell™ blood-group quality controls, reaches the market. FSL-Galili, the construct later developed as AGI-134, is first made.

A platform for almost any molecule · 2007–today

  1. 2007

    The CMG spacer extends FSL constructs beyond sugars to peptides and many other molecules.

  2. 2008

    FSL-biotin, a universal tool for attaching avidin-linked probes to surfaces.

  3. 2009

    Peptide kodecytes reach the market: AbtechCell™ III and Phenocell™ C, for blood-group antibody screening.

  4. 2010

    FSL constructs are inkjet-printed onto paper to map antibodies.

  5. 2010

    FSL constructs become available worldwide through the Sigma-Aldrich catalogue (now MilliporeSigma).

  6. 2014

    Dr Uri Galili finds that FSL-Galili outperforms the natural glycolipid he was using in cancer research.

  7. 2015

    Agalimmune licenses Kode Technology to develop FSL-Galili as a cancer immunotherapy.

  8. 2017

    A second FSL-Galili patent, with Kode Biotech inventors.

  9. 2022

    AGI-134, a Gen 2 KIE, completes a Phase 1/2a study in 38 late-stage human patients.

  10. 2023

    The Kode Technology Illustrated Technical Manual is published, covering all known Kode Technology data.

  11. 2025

    Stephen Henry is awarded a DSc by the University of Auckland for his thesis on Kode Technology.

  12. Today

    Kv9, a Gen 3 KIE for veterinary cancer, is in clinical trials.

  13. Today

    K5K, a Gen 3 KIE for human cancer, is in pre-clinical development.

the Kode Immunoeducer pipeline our story

The science: read the full story

Stephen Henry's DSc thesis and the Technical Manual tell the full story of Kode Technology.